ABBOTT DIABETES CARE LIMITED
Get an alert when ABBOTT DIABETES CARE LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£3.8m
Latest balance sheet
Net assets
£508m
Equity attributable
Employees
822
Average over period
Profit before tax
£537m
Period ending 2023-12-31
Net assets
1-year trend · vs Health Care median
Accounts
1-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | Δ vs prior |
|---|---|---|---|
| Turnover | £181,273,000 | — | |
| Operating profit | £541,800,000 | — | |
| Profit before tax | £536,723,000 | — | |
| Net profit | £401,701,000 | — | |
| Cash | £3,819,000 | — | |
| Total assets less current liabilities | £508,432,000 | — | |
| Net assets | £508,391,000 | — | |
| Equity | £508,391,000 | — | |
| Average employees | 822 | — | |
| Wages | £42,460,000 | — | |
| Directors' remuneration | £1,014,000 | — | |
| Directors' pension contributions | £111,000 | — | |
| Highest paid director | £477,000 | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. Year-on-year comparison hidden: this filing's period length differs materially from the prior year. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 |
|---|---|---|
| Return on capital employed | 106.6% | |
| Gearing (liabilities / total assets) | 35.2% | |
| Current ratio | 2.47x | |
| Interest cover | 53.61x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.
Name history
Renamed 2 times since incorporation
- ABBOTT DIABETES CARE LIMITED 2005-08-02 → present
- MEDISENSE UK LIMITED 1997-04-21 → 2005-08-02
- MEDISENSE (U.K.) HOLDING LTD. 1990-10-12 → 1997-04-21
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Therefore, after making enquiries, the Directors have a reasonable expectation that the Company will continue in operational existence for a period of twelve months from the approval of the financial statements.”
Significant events
- “On 23 July 2026, the Directors declared an interim dividend of the GBP equivalent of USD 650,000,000 payable to Abbott Laboratories Limited.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
5 active · 30 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| KENNY, Paul John | Secretary | 2019-03-07 | — | — |
| BASS, Christopher Graham | Director | 2016-11-10 | Jul 1982 | British |
| KENNY, Paul John | Director | 2019-03-07 | Oct 1967 | British |
| SMITH, Shaun Julian | Director | 2018-10-24 | Jul 1965 | British |
| WENNER, James Russell | Director | 2025-12-10 | Sep 1967 | American |
Show 30 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BASS, Christopher Graham | Secretary | 2016-11-10 | 2019-03-07 |
| BOJAS, Gerald J | Secretary | 1993-06-14 | 1993-08-03 |
| CROCKETT, Adrian Graham | Secretary | 2015-07-23 | 2016-11-01 |
| EVANS, Brian Nigel | Secretary | 1996-11-15 | 2015-07-24 |
| MCDONALD, James Angus | Secretary | 1993-08-03 | 2009-02-02 |
| WOLF, Rhoda Louvain | Secretary | — | 1993-05-07 |
| BOJAS, Gerald J | Director | 1993-06-14 | 1993-08-03 |
| BOJAS, Gerald J | Director | — | 1996-11-15 |
| BRANIGHAN, Kenneth Robert | Director | 2001-01-16 | 2002-06-21 |
| CARTER, Nigel | Director | 2000-07-24 | 2003-02-07 |
| COLE, Pat | Director | 2011-05-27 | 2018-10-25 |
| CROCKETT, Adrian Graham | Director | 2011-10-31 | 2016-11-01 |
| DAVIES, Alison Elizabeth | Director | 2023-10-15 | 2025-12-10 |
| FREYMAN, Thomas Craig | Director | 2001-04-01 | 2016-11-01 |
| GIBSON, Nathan Lee | Director | 1998-03-25 | 2000-07-24 |
| IGLESIAS FERNANDEZ, Luis | Director | 2002-06-26 | 2005-12-13 |
| KENNY, Paul John | Director | 2009-07-13 | 2011-10-31 |
| KRAMMER, Karen Ann | Director | 2020-03-27 | 2022-10-03 |
| LOGUE, Fraser, Dr | Director | 2007-03-20 | 2011-05-27 |
| MCCOY JR, John Arthur | Director | 2022-10-03 | 2023-10-15 |
| MCDONALD, James Angus | Director | 2003-02-07 | 2009-02-02 |
| MCDONALD, James Angus | Director | 1993-08-03 | 1997-05-30 |
| MUIR, Andrew Redvers, Dr | Director | 1992-08-11 | 1993-05-18 |
| PETERSON, Karen Marie | Director | 2020-03-01 | 2020-03-27 |
| QUINN JR., George P | Director | 1993-06-14 | 1993-08-03 |
| SCHUELER, John Otto | Director | 1997-12-22 | 2001-01-16 |
| SCOTT, David, Dr | Director | — | 1992-11-09 |
| WHELAN, Anthony John | Director | 2003-10-31 | 2007-03-20 |
| WOLF, Rhoda Louvain | Director | — | 1993-05-07 |
| YOOR, Brian | Director | 2016-11-10 | 2020-02-29 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Abbott Laboratories | Corporate entity | Appoints directors, Appoints directors (as firm) | 2016-04-06 | Ceased 2016-04-06 |
| Abbott Laboratories Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Active |
Filing timeline
Last 20 of 174 total filings
Material constitutional events — rename, articles re-file, resolution
- 2022-01-11 RESOLUTIONS Resolution
- 2022-01-11 MA Memorandum articles
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-09-07 | AA | accounts | Accounts with accounts type full | |
| 2025-12-15 | AP01 | officers | Appoint person director company with name date | |
| 2025-12-15 | TM01 | officers | Termination director company with name termination date | |
| 2025-10-13 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-09-08 | AA | accounts | Accounts with accounts type full | |
| 2024-11-20 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-10-12 | AA | accounts | Accounts with accounts type full | |
| 2023-11-02 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-10-25 | AP01 | officers | Appoint person director company with name date | |
| 2023-10-25 | TM01 | officers | Termination director company with name termination date | |
| 2023-09-22 | AA | accounts | Accounts with accounts type full | |
| 2022-10-25 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2022-10-12 | AA | accounts | Accounts with accounts type full | |
| 2022-10-03 | AP01 | officers | Appoint person director company with name date | |
| 2022-10-03 | TM01 | officers | Termination director company with name termination date | |
| 2022-01-11 | RESOLUTIONS | resolution | Resolution | |
| 2022-01-11 | MA | incorporation | Memorandum articles | |
| 2021-12-14 | SH01 | capital | Capital allotment shares | |
| 2021-10-12 | AA | accounts | Accounts with accounts type full | |
| 2021-10-12 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.